Mesothelioma Imaging Tests: X-Rays, CT, PET-CT and MRI

Mesothelioma Imaging Tests at a Glance

How Imaging Is Used in Mesothelioma Care

Imaging is used throughout mesothelioma care. Initial tests such as X-ray, ultrasound, or CT may be performed for persistent chest or abdominal symptoms. If abnormalities are detected, cross-sectional imaging defines their location and extent. Imaging also guides fluid sampling or biopsy, and after diagnosis, supports staging, treatment planning, and follow-up.

For the full diagnostic pathway, see Mesothelioma Diagnosis. For tissue-sampling procedures, see Tests and Biopsy.

Chest X-Ray

A chest X-ray is often the first imaging test for symptoms like breathlessness, cough, or chest discomfort. It can reveal pleural effusion, thickening, loss of lung volume, or other changes that may require further evaluation. These findings are not specific to cancer and may have other causes.

CT Scan

Computed tomography (CT) is the primary cross-sectional imaging method for evaluating pleural mesothelioma and is also widely used for peritoneal disease. CT provides detailed images of the pleura, lungs, mediastinum, chest wall, diaphragm, lymph nodes, and upper abdominal structures, offering greater detail than chest X-ray.

For pleural mesothelioma, current ASCO guidance recommends chest and upper abdominal CT with intravenous contrast as the initial staging study. CT helps map tumor distribution, identify pleural masses or thickening, assess effusions, detect fissural involvement, and evaluate possible extension into adjacent structures. It also identifies lesions suitable for image-guided biopsy.

What CT Can Show in Pleural Mesothelioma

• Nodular or diffuse pleural thickening and pleural masses
• Pleural effusion and loss of volume in the affected hemithorax
• Fissural involvement
• Possible chest-wall, diaphragmatic or mediastinal invasion
• Enlarged or suspicious lymph nodes
• Contralateral pleural abnormalities
• Possible abnormalities in the upper abdomen or distant sites included in the scan field

No single CT finding is specific for diagnosis. Radiologists assess the overall pattern and correlate it with clinical history, previous imaging, and pathology.

CT for Peritoneal Mesothelioma

In peritoneal mesothelioma, CT may reveal ascites, peritoneal or mesenteric thickening, nodules, masses, or omental abnormalities. A 2022 systematic review found CT is the most commonly used imaging modality in peritoneal mesothelioma studies, while MRI and PET-CT may offer additional information in selected cases. Imaging helps map disease but may underestimate small or microscopic disease.

See Peritoneal Mesothelioma for the site-specific diagnostic and treatment context.

CT Contrast and Preparation

Intravenous contrast enhances visualization of vessels and soft tissues and is commonly used for staging CT. Its use depends on the clinical question and individual factors such as kidney function, prior contrast reactions, and other medical considerations.

Ultrasound

Ultrasound uses sound waves instead of ionizing radiation. In mesothelioma care, it is especially useful for detecting pleural or abdominal fluid and guiding procedures such as thoracentesis, paracentesis, or selected needle biopsies. Real-time imaging helps clinicians select a safe path to superficial targets.

Ultrasound is not a comprehensive staging tool for pleural mesothelioma and cannot independently confirm the diagnosis. Its primary role is in assessing fluid, superficial structures, and guiding procedures.

FDG PET-CT

FDG PET-CT combines CT images with positron emission tomography after administration of fluorodeoxyglucose (FDG), a glucose-based radiotracer. Areas with increased metabolic activity show higher tracer uptake. In pleural mesothelioma, PET-CT aids initial staging, evaluation of nodal or distant disease, and selection of metabolically active biopsy targets.

Current ASCO guidance recommends FDG PET-CT for initial staging of pleural mesothelioma but notes that it may be omitted in patients who are not being considered for definitive surgical resection. Imaging decisions are individualized rather than standardized for all patients.

Limitations of PET-CT

FDG uptake is not specific to cancer; infection, inflammation, healing tissue, and other malignancies can also show FDG avidity. Small lesions or tumors with low metabolic activity may be less visible.

MRI

Magnetic resonance imaging (MRI) uses a strong magnetic field and radiofrequency signals instead of X-rays. MRI is not routinely required for all mesothelioma patients but is useful when additional soft-tissue detail is needed.

In pleural mesothelioma, MRI can clarify suspected invasion of the diaphragm, chest wall, mediastinum, or other structures when CT findings are inconclusive and local extent may influence treatment planning. Current ASCO guidance states that MRI, preferably with intravenous contrast when appropriate, may be obtained to further assess local invasion.

Before MRI, patients should inform the imaging team about implanted devices, metal fragments, prior procedures, kidney issues, pregnancy or possible pregnancy, and previous contrast reactions. The radiology team will determine if MRI and contrast are appropriate for each individual.

Imaging Rare Mesothelioma Sites

Pericardial mesothelioma

Primary pericardial mesothelioma is extremely rare, and no standardized imaging pathway exists comparable to the pleural-mesothelioma pathway. Echocardiography may reveal pericardial effusion, thickening, a mass, or hemodynamic effects. CT and cardiac MRI can better define pericardial thickening or masses and their relationship to the heart and adjacent structures. These findings are nonspecific; definitive diagnosis relies on pathologic examination when tissue can be obtained.

See Pericardial Mesothelioma.

Mesothelioma of the tunica vaginalis

Mesothelioma of the tunica vaginalis originates from the serosal lining around the testis and differs from typical testicular cancer. Scrotal ultrasound may detect a hydrocele, nodular thickening, or paratesticular masses, but these findings are not specific for diagnosis. Evidence comes mainly from case reports and case series, and definitive diagnosis is established by pathologic examination.

For the anatomical classification, see Types of Mesothelioma.

How Imaging Helps Guide Biopsy

Imaging helps select a safe and informative target for tissue sampling. CT or ultrasound can guide a needle to accessible pleural, chest-wall, or abdominal lesions. PET-CT may identify metabolically active areas for biopsy, while CT defines the surrounding anatomy. The clinical team chooses the sampling method based on tumor location, expected tissue yield, procedural risk, and treatment goals.

For details about thoracentesis, core biopsy, thoracoscopy and laparoscopy, see Mesothelioma Tests and Biopsy.

Imaging and Mesothelioma Staging

Diagnosis and staging serve different purposes. Diagnosis identifies the disease, while staging determines its extent. CT or PET-CT may inform the diagnostic work-up and staging, but imaging does not replace pathologic confirmation.

For pleural mesothelioma, chest and upper abdominal CT are central to clinical staging, and PET-CT can help identify nodal or distant disease. MRI may provide additional local staging information in selected cases. Enlarged or PET-avid lymph nodes may still require pathologic sampling if results would affect management.

Formal pleural staging is covered in Mesothelioma Stages. The pleural TNM system should not simply be applied to peritoneal, pericardial, or tunica-vaginalis mesothelioma.

Monitoring Treatment Response

Follow-up CT is commonly used to monitor pleural disease over time. Measuring pleural mesothelioma is challenging because the tumor often grows as an irregular rind along the chest wall rather than as a single mass.

Modified RECIST criteria were developed specifically to make pleural-mesothelioma measurements more reproducible, and the current ASCO guideline recommends modified RECIST 1.1 for tumor-response classification. Trained radiologists and research teams perform these measurements; patients are not expected to measure tumor thickness on their own scans.

Small differences between reports do not necessarily indicate treatment failure or disease progression. Scan technique, measurement location, pleural inflammation, and other factors can affect interpretation. The oncology team reviews imaging alongside symptoms, pathology, treatment timing, and other clinical information.

For treatment context, see Mesothelioma Treatment, and for broader outcome factors see Mesothelioma Prognosis.

Can Imaging Screen for Mesothelioma?

Diagnostic imaging and screening serve different purposes. Diagnostic imaging investigates symptoms or abnormal findings, while screening tests asymptomatic individuals to detect disease before symptoms appear.

For exposure context, see Mesothelioma Causes.

Preparing for an Imaging Appointment

Preparation varies by examination and imaging center. Some CT or MRI studies require contrast, and PET-CT often has specific instructions regarding eating, blood glucose, and medication timing. Patients should follow the instructions provided for their specific appointment rather than applying general rules from other scans.

1. Bring or provide access to prior scans when requested so the radiologist can compare changes over time.
2. Tell the imaging team about pregnancy or possible pregnancy before tests that may involve ionizing radiation or contrast.
3. Report previous contrast reactions, kidney disease, implanted devices, and relevant allergies.
4. Ask whether medications should be taken normally on the day of the examination; do not stop prescribed medicines without specific instructions.
5. For PET-CT, follow the center’s fasting, activity, and diabetes-related instructions because preparation can affect image quality.

Understanding Your Radiology Report

A radiology report typically describes the examination, relevant findings, comparisons with prior studies, and the radiologist’s impression. Terms like “pleural thickening,” “effusion,” “FDG avidity,” “mass,” or “enlarged lymph node” are imaging observations and do not confirm a cancer diagnosis.

If a report is unclear, the treating clinician can explain which findings are significant and whether they affect diagnosis or treatment. In complex cases or when major surgery is considered, a specialist radiology review may be helpful, especially if local invasion or disease extent is uncertain.

Questions to Ask Your Medical Team

1. What question is this imaging test intended to answer?
2. Why are you recommending CT, PET-CT, MRI, ultrasound or another test in my situation?
3. Will contrast be used, and is there anything I need to do beforehand?
4. How will this scan affect the decision about biopsy or treatment?
5. Are any findings likely to be affected by a recent biopsy, surgery, infection, or pleurodesis?
6. Which findings are related to diagnosis, and which are being used for staging?
7. Will my scan be compared with previous imaging?
8. If the report is uncertain, would specialist radiology review be useful?
9. How will you decide when the next scan is needed?

Frequently Asked Questions

References

1. National Cancer Institute. Mesothelioma Diagnosis & Prognosis. Updated May 16, 2025. View source.
2. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006–1038. PMID: 39778125. doi:10.1200/JCO-24-02425.
3. Katz SI, Straus CM, Roshkovan L, et al. Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group. Journal of Thoracic Oncology. 2023;18(3):278–298. PMID: 36549385. doi:10.1016/j.jtho.2022.11.018.
4. Strange CD, Marom EM, Ahuja J, Shroff GS, Gladish GW, Carter BW, Truong MT. Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma. Advances in Anatomic Pathology. 2023;30(4):280–291. PMID: 36395181. doi:10.1097/PAP.0000000000000386.
5. Armato SG 3rd, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). Journal of Thoracic Oncology. 2018;13(7):1012–1021. PMID: 29753121. doi:10.1016/j.jtho.2018.04.034.
6. Genestreti G, Moretti A, Piciucchi S, et al. FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy. Journal of Cancer. 2012;3:241–245. PMID: 22670158. doi:10.7150/jca.2586.
7. Carlson B, Harmath C, Turaga K, Kindler HL, Armato SG 3rd, Straus C. The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. Abdominal Radiology. 2022;47(5):1725–1740. PMID: 35257201. doi:10.1007/s00261-022-03464-x.
8. Bonde A, Singh R, Prasad SR, et al. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings. RadioGraphics. 2023;43(3):e220128. PMID: 36757881. doi:10.1148/rg.220128.
9. Grogg JB, Fronzaroli JN, Oliveira P, et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. Journal of Cancer Research and Clinical Oncology. 2021;147(9):2671–2679. PMID: 33559739. doi:10.1007/s00432-021-03533-6.
10. Zwijsen K, Heirwegh E, Schillebeeckx E, et al. Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and Recommendations. Lung Cancer. 2026;212:108893. PMID: 41512380. doi:10.1016/j.lungcan.2025.108893.